


AIDS VACCINE TRIALS 2004: YEAR IN REVIEW

This map depicts the clinical trials of preventive AIDS vaccines that began in 2004. For some of these trials additional sites will be added in 2005; the currently planned additional sites are represented here by dashed lines. For updated information or further details about a specific trial, please visit the IAVI Vaccine Trials Database (www.iavi.org/trialsdb). Please also e-mail any additions or comments to trialsdb@iavi.org.



April — USA
N/A
Phase I, 36 volunteers
gag + 5 env DNA (A, B, C, E); 5 rgp120 (A, B, C, E)
UMMS; ABL

April — USA
HVTN 056
Phase I, 96 volunteers
HIV CTL MEP (B)
NIAID; WYETH

May — USA
N/A
Phase I, 18 volunteers
LF₁-p24 (B)
NIAID, WRAIR; AVANT

May — USA
VRC 006 (04-I-0172)
Phase I, 36 volunteers
VRC-HIVADV014-00-VP (B); VRC-HIVADV014-00-VP (A, B, C)
NIAID; GENVEC

June — USA
HVTN 042/ANRS VAC 19
Phase I/II, 174 volunteers
LIPO-5 (B); ALVAC-HIV (vCP1452) (B)
HVTN, ANRS; AVENTIS

January — Thailand, Brazil, Haiti, Puerto Rico
(Later: Malawi)
HVTN 050/Merck 018
Phase I, 435 volunteers
MRKA₅ HIV-1 gag (B)
NIAID; MERCK

December — USA (Later: Peru, Dominican Republic, Haiti, Puerto Rico, Australia, Canada)
HVTN 502/Merck023
Phase IIb, 1500 volunteers
MRKA₅ HIV-1 gag/pol/nef (B)
HVTN, MERCK; MERCK

July — USA
HVTN 055
Phase I, 150 volunteers
TBC-M358 (MVA) (B); TBC-M335 (MVA) (B); TBC-F357 (FPV) (B); TBC-F349 (FPV) (B)
NIAID; THERION

August — USA
VRC 007 (04-I-0254)
Phase I, 15 volunteers
VRC-HIVDNA016-00-VP (A, B, C)
NIAID/VRC; VICAL

October — USA
HVTN 059
Phase I, 96 volunteers
AVX101 (VEE) gag (C)
NIAID; ALPHA VAX

November — USA
HVTN 057 (rollover from HVTN 052)
Phase I, 70 volunteers
VRC-HIVADV014-00-VP (A, B, C)
NIAID/VRC; VICAL

January 2005 — USA
IAVI C002
Phase I, 48 volunteers
ADMVA (C)
IAVI; IDT

July — France
ANRS VAC 16
Phase I, 70 volunteers
LIPO-4T (B)
ANRS; BIOVECTOR SA

September — France
ANRS VAC 18
Phase II, 132 volunteers
LIPO-5 (B)
ANRS; AVENTIS

February — Finland
C060301
Phase I/II, 28 volunteers
GTU-MultiHIV (B)
FIT BIOTECH

TRIAL INFORMATION

- Month — Countries
- Trial Number
- Phase, No. volunteers
- VACCINE (CLADE)
- TRIAL SPONSOR; MANUFACTURER

MAP KEY

VACCINE TYPE

- DNA
- Viral Vector
- Protein Subunit

COLOR KEY

- Dark green denotes countries where trials are currently ongoing.
- Light green indicates countries where trials will soon begin.

Abbreviations: ABL: Advanced BioScience Laboratories, Inc.; AlphaVax: AlphaVax Human Vaccines Inc.; ANRS: Agence Nationale de Recherche sur le SIDA; AVANT: AVANT Immunotherapeutics, Inc.; Aventis: Aventis Pasteur; Biovector SA: Biovector Therapeutics, SA; HVTN: HIV Vaccine Trials Network; IAVI: International AIDS Vaccine Initiative; IDT: Impfstoffwerk Dessau Tornau GmbH; NIAID: US National Institute Allergy and Infectious Diseases; Therion: Therion Biologics Corporation; UMMS: University of Massachusetts Medical School; VRC: Dale and Betty Bumpers Vaccine Research Center at the US National Institutes of Health; WRAIR: Walter Reed Army Institute of Research.